Table 1.
The anticancer effect of amniotic membrane cells or conditioned medium and underlying mechanism.
| Cell type | Targeted cell line/Cancer type | Cellular effect | Molecular effect | Ref |
|---|---|---|---|---|
| Amniotic epithelial cells | Human cervical carcinoma (Hela) and breast cancer (MDA-MB-231) | - Decrease of cancer cell viability - Anti-angiogenic - Apoptosis induction |
Increase of caspase-3,-8 | 11 |
| Amniotic mesenchymal cells | Acute myelogenous leukemia (KG1 cells), T-cell leukemia (Jurkat), monocytes from histiocytic lymphoma (U937), Human cervical carcinoma (Hela) | Anti-proliferative | Cell cycle arrest in G0/G1 phase | 31 |
| Amniotic mesenchymal cells | Brain tumor (C6-glioma) | - Inhibition of cell migration - Apoptosis induction |
--- | 36 |
| Amniotic epithelial and/or mesenchymal cells | Hepatocarcinoma (HuH7, HepG2, and Hep3B2.1-7) | - Apoptosis Induction - Inducing cell morphology alterations, - Inducing HCC cytotoxicity and cell death |
- Reduction the metabolic activity - Increase in cytochrome. C release, BAX/BCL2 ratio, - Increase in caspase 3, caspase 8, and caspase 9 |
39 |
| Amniotic epithelial cells | T-cell leukemia (Jurkat) | Apoptosis induction | Caspase-3 pathway | 43 |
| hAM- protein extract | Prostate cancer (PC3), colon cancer (WiDr, C2BBe1, LS1034), pancreas cancer (PANC-1), hepatocarcinoma (HepG-2, Hep3B2.1-7), breast cancer (MCF7, HCC1954), bile ducts (TFK-1) | --- | Different inhibit the metabolic activity depend on
particular genetic profile of each cell line - Increase of metabolic activity in C2BBe1, LS1034, HCC1954 and TFK-1 cell lines. - Reduction of metabolic activity in PANC1, HepG2, Hep3B2.1-7 WiDr and PC3 cell lines |
47 |
| hAM- protein extract | Prostate cancer (PC3) | Reduction of cell proliferation | Decrease in gene expression and HSP90 protein expression | 75 |